Future research will be needed to determine a detailed mechanistic relationship between PRAS40–P65 interaction and the oncogenic processes of lung cancer cells, and the discovery of a small truncation peptide (P65 180-200) in this study, capable of disrupting the PRAS40–p65 association, will facilitate future research in this area. The gene discussed is AKT1S1; the disease is lung carcinoma.